Amneal Pharmaceuticals, Inc. AMRX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net revenue by Business | |||||
| Affordable Medicines | $1.75B+3.6% | $1.69B+14.5% | $1.47B+2.7% | $1.43B— | |
| AvKARE | $744.73M+12.3% | $662.95M+24.7% | $531.75M+30.9% | $406.11M+16.4% | |
| Net revenue by Product | |||||
| Auto-Injector | $232.8M+11.1% | $209.5M+30.2% | $160.85M+14.4% | $140.56M— | |
| Biosimilar | $100.23M-20.1% | $125.42M+90.3% | $65.92M+1,934% | $3.24M— | |
| Central nervous system | $333.42M+19.0% | $280.17M— | —— | —— | |
| Distribution | $408.46M-5.9% | $433.98M+24.9% | $347.41M+33.3% | $260.56M+35.1% | |
| Government label | $270.11M+68.9% | $159.96M+31.3% | $121.83M+24.0% | $98.23M-17.0% | |
| Hormonal / allergy | $154.93M+18.8% | $130.43M— | —— | —— | |
| Injectable | $161.24M-2.5% | $165.43M+16.6% | $141.85M-24.9% | $188.94M— | |
| Institutional | $35.38M-17.2% | $42.75M+12.5% | $38.02M+37.0% | $27.74M+10.2% | |
| International | $12.13M+35.4% | $8.95M+313% | $2.17M+47.5% | $1.47M— | |
| Oral liquid | $72.82M-29.6% | $103.42M-6.9% | $111.05M+2.4% | $108.41M— | |
| Oral solid | $726.38M+5.4% | $689.44M+6.1% | $650M-0.4% | $652.74M— | |
| Other dosage forms | $252.42M+24.8% | $202.19M+12.0% | $180.48M-13.8% | $209.41M— | |
| Other therapeutic classes | $39.66M+38.6% | $28.62M— | —— | —— | |
| Subtotal dosage forms | $1.73B+3.4% | $1.68B+14.1% | $1.47B+3.3% | $1.42B— | |
| Subtotal therapeutic classes | $528.01M+20.2% | $439.22M+12.5% | $390.46M+4.4% | $374.12M— | |
| Transdermal | $187.51M+3.6% | $180.92M+13.7% | $159.08M+33.4% | $119.29M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amneal Pharmaceuticals, Inc. break its business down?
- Amneal Pharmaceuticals, Inc. (AMRX) reports net revenue by business across 3 parts — Affordable Medicines, AvKARE and Specialty. Each is extracted from the segment footnotes and tracked over time.
- Where does Amneal Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amneal Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
